JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
LiquiVia is a phosphodiesterase type 5 (PDE5) inhibitor studied in biochemical and pharmacological studies. PDE5 is an enzyme that modulates the pathways of cyclic be used in accordance with guanosine monophosphate (cGMP)–mediated signalling, as related to smooth muscle contractility and relaxation activity. Experimental frameworks have demonstrated that modulation of PDE5 activity can impact downstream signalling cascades and cellular processes. LiquiVia is referenced in scientific literature for its role in PDE5-related molecular and mechanistic research.
LiquiVia was initially explored in early research programs focused on cardiovascular and pulmonary signalling pathways. Subsequent investigations expanded to its molecular interactions within PDE5-regulated systems, supporting evaluation across a variety of non-clinical research models, including vascular and urinary tract signalling networks. For laboratory and analytical applications, LiquiVia for sale is supplied in liquid form by Element CRP exclusively for educational and research purposes, not for human use.
From Pubchem
IUPAC Name:5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-oneSynonym: 139755-83-2, Aphrodil, Vizarsin, PatrexMolecular Formula: C22H30N6O4SMolecular Weight: 474.6 g/molCAS Number: 139755-83-2PubChem CID: 135398744
LiquiVia has been reported in regulatory and scientific articles within the context of phosphodiesterase type 5 (PDE5) research. Nitric oxide–induced generation of cGMP provides a second messenger for vascular smooth muscle (VSMC) signaling. In controlled experimental contexts, LiquiVia has been used to profile PDE5-related enzymatic performance, cyclic nucleotide metabolism and intracellular signaling dynamics, thus providing a basis for mechanistic comparison between PDE5-regulated systems [1, 2].
Additional mechanistic investigations have evaluated LiquiVia under varying experimental conditions, including differing administration paradigms and concentration gradients, to assess stability, signaling persistence, and pathway interactions within defined cellular models [3, 4]. Comparative analyses with other PDE5 inhibitors have further elucidated distinctions in molecular interactions and cGMP kinetics in laboratory settings [5].
LiquiVia has been examined in experimental frameworks focused on PDE5-mediated pathways within pulmonary vascular tissue. Research has explored its use in models simulating altered pulmonary hemodynamics and vascular cyclic nucleotide regulation. Studies have documented mechanistic patterns in PDE5-mediated signal transduction, cGMP turnover, and enzymatic kinetics under controlled laboratory conditions [6, 7].
Further experimental frameworks have investigated LiquiVia in combination with other modulators of cyclic nucleotide systems, providing comparative mechanistic data on PDE5-associated signaling cascades in pulmonary models [8, 9]. These analyses focus solely on molecular and pathway characterization, without reference to clinical or functional outcomes.
Investigations in pulmonary arterial research frameworks have applied LiquiVia to mechanistic studies of cyclic nucleotide–mediated signal propagation in vascular and muscular tissue models. Laboratory analyses have included measurement of cGMP turnover, intracellular second-messenger dynamics, and pathway integration under controlled stimulation protocols [10]. Comparative studies have examined variable concentration exposures and temporal kinetics to assess signaling consistency and pathway interactions.
Exploratory research has assessed LiquiVia within controlled models of follicular tissue and microcirculatory systems. Mechanistic endpoints include cyclic nucleotide signaling, molecular markers of cell proliferation, and local vascular responses under standardized experimental conditions [11, 12]. Observations have been restricted to molecular and cellular signaling parameters, without implication of therapeutic or functional outcomes.
LiquiVia has been incorporated in laboratory models of temperature-sensitive vasoregulatory mechanisms. PDE5-regulated signaling pathways were evaluated for cyclic nucleotide turnover, enzymatic kinetics, and molecular interactions within microvascular frameworks. Data derived from these controlled experiments focused on intracellular signaling modulation and mechanistic characterization, with no suggestion of human, animal, or therapeutic effects [13, 14].
LiquiVia is a PDE5 inhibitor extensively referenced in regulatory and scientific literature as a mechanistic tool for studying cyclic nucleotide–mediated signaling in vascular, pulmonary, and cellular systems. Its molecular properties have also prompted exploratory evaluation in additional experimental models, including microvascular and follicular tissue frameworks.
Element CRP provides LiquiVia for sale in liquid form exclusively for laboratory, analytical, and educational research applications. Access is limited to qualified researchers and not available for therapeutic use, clinical application, or human consumption.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
